YB-0158 (Synonyms: Wnt pathway inhibitor 2)

Cell lines

HT29 cells

Preparation Method

Cells were treated with DMSO or YB-0158 for 48 hours. As a positive control, each cell line was treated with 1 µM of staurosporine for 6 h.

Reaction Conditions

0.2, 0.5µM for 48 hours

Applications

EdU incorporation confirmed that lower doses of YB-0158 were sufficient to significantly decrease proliferation in human CRC cells. When used at 0.5 µM, YB-0158 also significantly increased apoptosis in CRC cells as represented by activated Caspase-3/7 detection assays

Animal models

C57BL/6 mice accepted subcutaneous injection of MC38 cells into the flanks

Preparation Method

Seven days post-injection, daily doses of YB-0158 (100mg/kg), or control saline (HBSS vehicle) were intraperitoneally injected in tumor-bearing animals for 14 days.

Dosage form

Intraperitoneal injection, 100mg/kg

Applications

No significant differences in primary tumor size were observed upon either YB-0158 in vivo treatments versus saline controls, residual secondary tumors from YB-0158-treated group were significantly smaller versus matched saline controls.

References:

[1]: Angelique N. Masibag, Christopher J. Bergin, Joshua R. Haebe, AÏcha Zouggar, Muhammad S. Shah, Tamara Sandouka, Amanda Mendes da Silva, FranÇois M. Desrochers, Aube Fournier-Morin, Yannick D. Benoit.Pharmacological targeting of Sam68 functions in colorectal cancer stem cells. iScience, Volume 24, Issue 12, 17 December 2021, Pages 103442